The overexpression of AhR and/or its increased activity has been observed in a number of tumor types, including breast cancer, lung adenocarcinoma, gastric cancer, adult T-cell leukemia, pancreatic cancer, prostate cancer, urothelial carcinoma, human glioma or medulloblastoma [58]. This evidence concerns the gene AHR and prostate carcinoma.